Immunoradiotherapy for NSCLC: mechanisms, clinical outcomes, and future directions

被引：2
作者：
He, Weishan [1 ]
Zheng, Donglin [2 ]
Deng, Guangmei [1 ]
Liu, Wenya [1 ]
Wu, Fasheng [2 ]
Chen, Jibing [2 ]
机构：
[1] Guangxi Univ Chinese Med, Grad Sch, Nanning, Guangxi, Peoples R China
[2] Guangxi Univ Chinese Med, Ruikang Hosp, Nanning, Guangxi, Peoples R China
来源：
CLINICAL & TRANSLATIONAL ONCOLOGY | 2024年 / 26卷 / 05期
关键词：
Radiotherapy; Immunotherapy; Immune checkpoint inhibitor; Immunoradiotherapy; Non-small-cell lung cancer; PLAYER; PSGL-1;
D O I：
10.1007/s12094-023-03337-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Non-small-cell lung cancer (NSCLC) has an extremely low 5-year survival rate, with the only effective treatment being immunoradiotherapy (iRT). Here, we review the progress of clinical research on iRT for non-small-cell lung cancer (NSCLC) over 2018-2023, as well as the future directions. We first discuss the synergistic mechanisms of iRT, reflected in three aspects: immune regulation of RT, RT-activated immune-related pathways, and RT-related immune sensitization. iRT may include either external-beam or stereotactic-body RT combined with either immune checkpoint inhibitors (e.g., immunoglobulins against immune programmed cell death (PD) 1/PD ligand 1 or CD8+ T lymphocyte antigen 4) or traditional Chinese medicine drugs. Regarding clinical effectiveness and safety, iRT increases overall and progression-free survival and tumor control rate among patients with NSCLC but without a considerable increase in toxicity risk. We finally discuss iRT challenges and future directions reported over 2018-2023.
引用
收藏
页码：1063 / 1076
页数：14
相关论文
共 92 条
  • [1] cGAS in action: Expanding roles in immunity and inflammation
    Ablasser, Andrea
    Chen, Zhijian J.
    [J]. SCIENCE, 2019, 363 (6431) : 1055 - +
  • [2] Systematic review of case reports on the abscopal effect
    Abuodeh, Yazan
    Venkat, Puja
    Kim, Sungjune
    [J]. CURRENT PROBLEMS IN CANCER, 2016, 40 (01) : 25 - 37
  • [3] Radiotherapy and Immunotherapy Combinations for Lung Cancer
    Agrawal, Vishesh
    Benjamin, Kimberly Thomas
    Ko, Eric C.
    [J]. CURRENT ONCOLOGY REPORTS, 2021, 23 (01)
  • [4] Role of PD-1 during effector CD8 T cell differentiation
    Ahn, Eunseon
    Araki, Koichi
    Hashimoto, Masao
    Li, Weiyan
    Riley, James L.
    Cheung, Jeanne
    Sharpe, Arlene H.
    Freeman, Gordon J.
    Irving, Bryan A.
    Ahmed, Rafi
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2018, 115 (18) : 4749 - 4754
  • [5] Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
    Antonia, S. J.
    Villegas, A.
    Daniel, D.
    Vicente, D.
    Murakami, S.
    Hui, R.
    Kurata, T.
    Chiappori, A.
    Lee, K. H.
    de Wit, M.
    Cho, B. C.
    Bourhaba, M.
    Quantin, X.
    Tokito, T.
    Mekhail, T.
    Planchard, D.
    Kim, Y. -C.
    Karapetis, C. S.
    Hiret, S.
    Ostoros, G.
    Kubota, K.
    Gray, J. E.
    Paz-Ares, L.
    Carpeno, J. de Castro
    Faivre-Finn, C.
    Reck, M.
    Vansteenkiste, J.
    Spigel, D. R.
    Wadsworth, C.
    Melillo, G.
    Taboada, M.
    Dennis, P. A.
    Ozguroglu, M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (24) : 2342 - 2350
  • [6] ASAOKA Y, 2015, NEW ENGL J MED, V373, DOI DOI 10.1056/NEJMC1510353
  • [7] PACIFIC: shifting tides in the treatment of locally advanced non-small cell lung cancer
    Bang, Andrew
    Schoenfeld, Jonathan D.
    Sun, Alexander Y.
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 : S139 - S146
  • [8] Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial
    Bauml, Joshua M.
    Mick, Rosemarie
    Ciunci, Christine
    Aggarwal, Charu
    Davis, Christiana
    Evans, Tracey
    Deshpande, Charuhas
    Miller, Linda
    Patel, Pooja
    Alley, Evan
    Knepley, Christina
    Mutale, Faith
    Cohen, Roger B.
    Langer, Corey J.
    [J]. JAMA ONCOLOGY, 2019, 5 (09) : 1283 - 1290
  • [9] Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer
    Bradley, Jeffrey D.
    Hu, Chen
    Komaki, Ritsuko R.
    Masters, Gregory A.
    Blumenschein, George R.
    Schild, Steven E.
    Bogart, Jeffrey A.
    Forster, Kenneth M.
    Magliocco, Anthony M.
    Kavadi, Vivek S.
    Narayan, Samir
    Iyengar, Puneeth
    Robinson, Clifford G.
    Wynn, Raymond B.
    Koprowski, Christopher D.
    Olson, Michael R.
    Meng, Joanne
    Paulus, Rebecca
    Curran, Walter J., Jr.
    Choy, Hak
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (07) : 706 - +
  • [10] Time to abandon single-site irradiation for inducing abscopal effects
    Brooks, Eric D.
    Chang, Joe Y.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2019, 16 (02) : 123 - 135
12345678910